On Monday, February 26, 2024, BioMarin Pharmaceutical, Inc. (“BioMarin”) disclosed in its annual filing that the company recently received a subpoena from the U.S. Department of Justice (DOJ) requesting certain documents regarding BioMarin’s sponsored testing programs relating to two of its products, VIMIZIM and NAGLAZYME.[1] BioMarin also stated that the company “produced documents in response to the subpoena and are cooperating fully, but there is no assurance that such sponsored testing programs, or [BioMarin’s] other operations or programs, will not be ...
Blog Editors
Recent Updates
- Health Care Without the Hospital: ChatGPT Health and Claude Go Direct to Consumers
- The HTI-5 Proposed Rules: ASTP/ONC’s Cleanup and the Hard Work that Lies Ahead
- Just Released: Telemental Health Laws – Download Our Complimentary Survey and App
- OIG Limits Sign-On Bonuses to In-Home Family Caregivers
- Governing Health AI Development and Adoption: Insights from HHS’s Recently Announced Strategy to Promote AI in Healthcare